The Importance of a Tumor Capsule in Columnar Cell Thyroid Carcinoma: A Report of Two Cases and Review of the Literature

Yunta, P J; Ponce, José Luis; Prieto, Mireya; Merino, Francisco; S, Sancho-Fornos

doi:10.1089/thy.1999.9.815

Cited by 19 publications

(19 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because previous studies of these neoplasms have been largely limited to case studies, we reviewed reports in the English literature to date to better define the clinicopathological characteristics of these rare neoplasms. [1][2][3][4][5][6][7][8][9][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48] The 48 reported cases consisted of 15 men and 33 women. Men ranged in age from 29 to 77 years (mean 49.5 years, median 47 years) and women from 16 to 83 years (mean 49 years, median 50 years).…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma

et al. 2011

View full text Add to dashboard Cite

The majority of papillary thyroid carcinoma is indolent and associated with long-term survival. The columnar cell variant, however, is a rare subtype that is variable in biological behavior; some are clinically aggressive, whereas others are more clinically indolent. Tumor size, tumor circumscription, and encapsulation may influence the behavior of columnar cell carcinomas. Other variables including genetic changes and putative biomarkers associated with malignant growth have not been thoroughly examined in these neoplasms. In this study, nine cases of columnar cell variant of papillary thyroid carcinoma from three institutions were classified as clinically indolent or aggressive based on pathological features, clinical history, and outcome. Indolent tumors were typically small, circumscribed or encapsulated, and from younger female patients, whereas aggressive tumors were large, locally aggressive, associated with regional and distant metastasis, and from older male patients. The missense mutation, V600E in the BRAF oncogene (BRAF V600E ), was detected in three of nine of cases, of which two were clinically aggressive. Immunohistochemical evaluation of neoplasiaassociated markers showed increased nuclear cyclin D1 expression, elevated Ki-67 proliferation indices, and predominantly weak nuclear p53 staining in both indolent and aggressive tumors. Expression of b-catenin was largely restricted to a membranous pattern in both tumor types. Cytoplasmic expression of bcl-2 was overall mildly reduced in indolent neoplasms. Nuclear expression of estrogen and progesterone receptors was increased in both indolent and aggressive neoplasms, but was without sex-or age-related differences; however, whereas progesterone receptor expression was diffuse and strong in clinically indolent carcinomas, its expression was diminished in aggressive neoplasms. Recognition of the clinicopathological characteristics and the molecular and immunophenotypic features of the columnar cell variant of papillary thyroid carcinoma may aid in characterizing neoplasms that behave indolently or aggressively. Keywords: BRAF (BRAF V600E ); b-catenin; columnar cell variant; cyclin D1; papillary thyroid carcinoma Papillary thyroid carcinoma is a common endocrine neoplasm that is typically indolent and associated with long-term survival. This favorable biological behavior reflects the vast majority of conventional and histological variants of well-differentiated papillary thyroid carcinoma. However, a more aggressive tumoral growth characterizes a small subset that behaves more akin to poorly differentiated and undifferentiated thyroid carcinoma. Initially included in this group of aggressive neoplasms, the columnar cell variant is a rare subtype with variable biological behavior. Early reports described tumors with fast growth rates, aggressive local invasion, high rates of recurrence, early metastasis to regional lymph nodes and distant

show abstract

Section: Discussionmentioning

confidence: 99%

Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…11,12 Patients with encapsulated columnar cell thyroid carcinoma also have an excellent prognosis and should not be classified as PDTC. 13 Since some clinicians include clinical characteristics in defining PDTC, the literature is inconsistent, thus precluding any definitive conclusions regarding the disease process. It is preferable to limit this term to histologic criteria.…”

Section: Poorly Differentiated Thyroid Carcinomamentioning

confidence: 99%

Poorly Differentiated and Anaplastic Thyroid Cancer

2006

View full text Add to dashboard Cite

Background: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic (undifferentiated) thyroid carcinoma (ATC) comprise a small subset of thyroid tumors that are associated with a poor prognosis and account for Shaha, MD, FACS, Head and Neck Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. E-mail: shahaa@mskcc.org No significant relationship exists between the authors and the companies/organizations whose products or services may be referenced in this article. Abbreviations used in this paper: PDTC = poorly differentiated thyroid carcinoma, WDTC = well-differentiated thyroid carcinoma, ATC = anaplastic thyroid carcinoma, ITC = insular thyroid carcinoma, FNAB = fine-needle aspiration biopsy, TG = thyroglobulin, RAI = radioactive iodine, EBRT = external-beam radiation therapy.

show abstract

“…Individuals had used 131 I compounds for medullary thyroid carcinoma, but not papillary or follicular thyroid carcinoma. 1,[31][32][33][34][35][36][37] Tumor localization with the probe in position during surgery has not been previously described in the literature for differentiated thyroid carcinoma. However, the concept and surgery are similar to other radioguided procedures.…”

Section: Case Reportmentioning

confidence: 99%

Recombinant TSH-Stimulated, Radioguided Differentiated Thyroid Carcinoma Surgery

Spieth¹,

Standiford²,

Starkman³

et al. 2003

Clinical Medicine & Research

View full text Add to dashboard Cite

A novel approach to locating and surgically resecting occult metastatic foci in a 25-year-old female with a history of total thyroidectomy for differentiated thyroid carcinoma was attempted. Two iodine-131 (131I) body scans were performed: one after the patient underwent a 2-3 week thyroxine withdrawal, and another the following week utilizing recombinant TSH-stimulation. Then the patient was treated with 151 mCi of 131I, and 2 weeks later, without further hormonal manipulation, she had radioguided surgery. The two diagnostic 131I body scans were negative, but the post-therapy scan was positive. Two weeks later after pre-operative skin marking, radioguided surgery localized metastatic foci in the central compartment neck just dorsal to the suprasternal notch. No other foci were identified with the probe at surgery. At pathology, 2 of the 12 nodes were positive, as well as a 1 mm metastatic focus in the fat. Provocative imaging protocols, aggressive radioiodine therapy, and the novel use of radioguided surgery to attempt a cure in an 131I image-negative metastatic thyroid carcinoma patient was performed. No other cases using these combined diagnostic and therapeutic efforts have been reported in the literature.

show abstract

The Importance of a Tumor Capsule in Columnar Cell Thyroid Carcinoma: A Report of Two Cases and Review of the Literature

Cited by 19 publications

References 10 publications

Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma

Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma

Poorly Differentiated and Anaplastic Thyroid Cancer

Recombinant TSH-Stimulated, Radioguided Differentiated Thyroid Carcinoma Surgery

Contact Info

Product

Resources

About